These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 13597288)

  • 1. [Do anti-inflammatory agents modify verified hypocoagulability in dogs during various shocks liberating histamine or heparin].
    BINET L; QUIVY D
    C R Seances Soc Biol Fil; 1958; 152(3):419-21. PubMed ID: 13597288
    [No Abstract]   [Full Text] [Related]  

  • 2. [Does injection of a substituted butylamine, a histamine-liberator, cause release of heparin in dogs?].
    BINET L; QUIVY D
    C R Seances Soc Biol Fil; 1956; 150(12):2157-60. PubMed ID: 13437550
    [No Abstract]   [Full Text] [Related]  

  • 3. [Mechanism of action of histamine on blood coagulability].
    Kuznik BI; Basov VI; Tsybikov NN
    Farmakol Toksikol; 1972 Jul; 35(4):448-52. PubMed ID: 5050276
    [No Abstract]   [Full Text] [Related]  

  • 4. [Modifications of plasma coagulation in dog after injection of histamine].
    QUIVY D
    J Physiol (Paris); 1951; 43(4):848-51. PubMed ID: 14918161
    [No Abstract]   [Full Text] [Related]  

  • 5. [Blood coagulation in the dog during various types of shock induced by heparin and histamine liberators].
    QUIVY D
    Arch Int Pharmacodyn Ther; 1956 Mar; 105(3-4):429-37. PubMed ID: 13314749
    [No Abstract]   [Full Text] [Related]  

  • 6. No influence of intravenous ciprofloxacin on histamine release, complement activation, and blood clotting system.
    Wingender W; Beermann D; Konrad-Dalhoff I; Loof I; Eckert P
    J Chemother; 1989 Jul; 1(4 Suppl):608-10. PubMed ID: 16312554
    [No Abstract]   [Full Text] [Related]  

  • 7. [The effect of adrenochrome and histamine on the blood coagulation].
    KUSCHINSKY G; HILLE U; SCHIMASSEK H
    Klin Wochenschr; 1952 May; 30(17-18):421. PubMed ID: 14946973
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute inflammation in peritoneal dialysis: experimental studies in rats. Characterization of regulatory mechanisms.
    Bazargani F
    Swed Dent J Suppl; 2005; (171):1-57, i. PubMed ID: 15847249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Heparin treatment of hypertension; the effect of small repeated heparin injections on blood coagulation].
    KELLER R
    Medizinische; 1955 Apr; 14():492-5. PubMed ID: 14383075
    [No Abstract]   [Full Text] [Related]  

  • 11. [Inhibition of plasmatic coagulation: what is new?].
    Schwarz M; Bode C
    Hamostaseologie; 2006 May; 26(2):154-7. PubMed ID: 16676059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of heparin induced anti-cancer activity in experimental cancer models.
    Niers TM; Klerk CP; DiNisio M; Van Noorden CJ; Büller HR; Reitsma PH; Richel DJ
    Crit Rev Oncol Hematol; 2007 Mar; 61(3):195-207. PubMed ID: 17074500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery.
    Kim YS; Murkin JM; Adams SJ
    Heart Surg Forum; 2004; 7(6):E599-604. PubMed ID: 15769695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low molecular weight heparin treatment decreases MMP-9 plasma activity in patients with abdominal aortic aneurysm.
    Grzela T; Brawura-Biskupski-Samaha R; Jelenska MM; Szmidt J
    Eur J Vasc Endovasc Surg; 2008 Feb; 35(2):159-61. PubMed ID: 17964826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Histamine-liberating properties of a substituted butylamine (L 1935) in dogs].
    BRANELLEC A; BRIOT M; HALPERN BN; LIACOPOULOS P; NEVEU T
    C R Seances Soc Biol Fil; 1956; 150(7):1302-6. PubMed ID: 13397054
    [No Abstract]   [Full Text] [Related]  

  • 16. A combination of a thrombin inhibitor and dexamethasone prevents the development of experimental disseminated intravascular coagulation in rats.
    Elg M; Gustafsson D
    Thromb Res; 2006; 117(4):429-37. PubMed ID: 15869787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin release is insufficient in syringes with platelets as heparin source.
    Gruber M; Spaeth R; Bechmann V
    Clin Chim Acta; 2008 Sep; 395(1-2):187. PubMed ID: 18515082
    [No Abstract]   [Full Text] [Related]  

  • 18. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evidence of gender-related heparin resistance.
    Monte S; Lyons G
    Int J Obstet Anesth; 2004 Apr; 13(2):91-4. PubMed ID: 15321411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
    Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
    Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.